TScan Therapeutics (TScan Therapeutics) Net Margin % : -271.99% (As of Dec. 2023)

View and export this data going back to 2021. Start your Free Trial

What is TScan Therapeutics Net Margin %?

Net margin is calculated as Net Income divided by its Revenue. TScan Therapeutics's Net Income for the three months ended in Dec. 2023 was $-19.61 Mil. TScan Therapeutics's Revenue for the three months ended in Dec. 2023 was $7.21 Mil. Therefore, TScan Therapeutics's net margin for the quarter that ended in Dec. 2023 was -271.99%.

The historical rank and industry rank for TScan Therapeutics's Net Margin % or its related term are showing as below:

TCRX' s Net Margin % Range Over the Past 10 Years
Min: -2408.02 Med: -484.38 Max: -423.86
Current: -423.86

TCRX's Net Margin % is ranked worse than
63.19% of 1027 companies
in the Biotechnology industry
Industry Median: -162.58 vs TCRX: -423.86

TScan Therapeutics Net Margin % Historical Data

The historical data trend for TScan Therapeutics's Net Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

TScan Therapeutics Net Margin % Chart

TScan Therapeutics Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Dec23

Net Margin %

-2,408.02

-479.49

-489.26

-423.86

TScan Therapeutics Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Net Margin %	Get a 7-Day Free Trial												-604.94	-331.66	-763.82	-591.64	-271.99

Competitive Comparison of TScan Therapeutics's Net Margin %

For the Biotechnology subindustry, TScan Therapeutics's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

TScan Therapeutics's Net Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, TScan Therapeutics's Net Margin % distribution charts can be found below:

* The bar in red indicates where TScan Therapeutics's Net Margin % falls into.

TScan Therapeutics Net Margin % Calculation

Net margin - also known as net profit margin is the ratio of Net Income divided by net sales or Revenue, usually presented in percent.

TScan Therapeutics's Net Margin for the fiscal year that ended in Dec. 2023 is calculated as

Net Margin	=	Net Income (A: Dec. 2023 )	/	Revenue (A: Dec. 2023 )
	=	-89.218	/	21.049
	=	-423.86 %

TScan Therapeutics's Net Margin for the quarter that ended in Dec. 2023 is calculated as

Net Margin	=	Net Income (Q: Dec. 2023 )	/	Revenue (Q: Dec. 2023 )
	=	-19.613	/	7.211
	=	-271.99 %

TScan Therapeutics (NAS:TCRX) Net Margin % Explanation

Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.

But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.

TScan Therapeutics Net Margin % Related Terms

Thank you for viewing the detailed overview of TScan Therapeutics's Net Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

TScan Therapeutics (TScan Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » TScan Therapeutics Inc (NAS:TCRX) » Definitions » Net Margin %

Comparable Companies

Traded in Other Exchanges

N/A

Address

830 Winter Street, Waltham, MA, USA, 02451

Website

https://www.tscan.com

TScan Therapeutics Inc is a biopharmaceutical company focused on the development of T-cell receptor (TCR) engineered T cell therapies (TCR-T) for the treatment of patients with cancer. The company's liquid tumor TCR-T therapy candidates, TSC-100 and TSC-101, are in development for the treatment of patients with hematologic malignancies to eliminate residual leukemia and prevent relapse after hematopoietic stem cell transplantation. It is also developing multiplexed TCR-T therapy candidates for the treatment of various solid tumors.

Executives

Timothy J Barberich	director	40 ELM ST, CONCORD MA 01752
Barbara Klencke	director	C/O SIERRA ONCOLOGY, INC., 1820 GATEWAY DRIVE, SUITE 110, SAN MATEO CA 94404
Leiden Dworak	officer: Chief Accounting Officer	C/O TSCAN THERAPEUTICS, INC., 880 WINTER STREET, WALTHAM MA 02451
Lynx1 Capital Management Lp	10 percent owner	151 CALLE DE SAN FRANCISCO, SUITE 200 PMB 1237, SAN JUAN PR 00901-1607
Weston Nichols	10 percent owner	C/O CRINETICS PHARMACEUTICALS, INC., 10222 BARNES CANYON ROAD, BLDG. #2, SAN DIEGO CA 92121
Ecor1 Capital, Llc	10 percent owner	357 TEHAMA STREET #3, SAN FRANCISCO CA 94103
Brian M. Silver	officer: Chief Financial Officer	C/O TSCAN THERAPEUTICS, INC., 830 WINTER STREET, WALTHAM MA 02451
Debora Barton	officer: Chief Medical Officer	C/O TSCAN THERAPEUTICS, INC., 830 WINTER STREET, WALTHAM MA 02451
David P Southwell	director, officer: Chief Executive Officer	C/O INOTEK PHARMACEUTICALS CORPORATION, 91 HARTWELL AVENUE, LEXINGTON MA 02421
Baker Bros. Advisors Lp	director, 10 percent owner	860 WASHINGTON STREET, 3RD FLOOR, NEW YORK NY 10014
Julian Baker	director, 10 percent owner	BAKER BROS. ADVISORS LP, 860 WASHINGTON STREET 3RD FLOOR, NEW YORK NY 10014
Baker Bros. Advisors (gp) Llc	director, 10 percent owner	860 WASHINGTON STREET, 3RD FLOOR, NEW YORK NY 10014
L.p. 667,	director, 10 percent owner	860 WASHINGTON STREET, 3RD FLOOR, NEW YORK NY 10014
Baker Brothers Life Sciences Lp	director, 10 percent owner	860 WASHINGTON STREET, 3RD FLOOR, NEW YORK NY 10014
Felix Baker	director, 10 percent owner	BAKER BROS. ADVISORS LP, 860 WASHINGTON STREET 3RD FLOOR, NEW YORK NY 10014